The Union Health Ministry is in discussions with state governments on the possibility of granting additional time to certain pharmaceutical manufacturers to comply with revised Good Manufacturing Practices (GMP) norms under Schedule M of the Drug...
Dr. Reddy’s Labs receives a USFDA CRL for AVT03 denosumab biosimilar, citing manufacturing inspection issues, delaying approval in the key US biologics market.
Cupid has received in-principle approval from its Board of Directors to establish a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA), marking the company’s first manufacturing venture outside India.
Amneal Pharmaceuticals Inc. got an approval from the FDA for two denosumab biosimilars, growing their biosimilar offerings in the US.
Ajanta Pharma partners with Biocon to launch Semaglutide in emerging markets, boosting GLP-1 therapy access, therapeutic leadership, and commercial growth in diabetes care.
In 2025, India’s pharmaceutical sector is demonstrating remarkable dynamism, driven by a blend of global collaborations and homegrown innovation.
In 2025, India’s pharmaceutical sector is demonstrating remarkable dynamism, driven by a blend of global collaborations and homegrown innovation.
Cipla has launched Afrezza, a rapid-acting inhalable insulin, marking a new addition to diabetes treatment options in India. The product offers a needle-free alternative to injectable mealtime insulin and is aimed at improving ease of use and trea...
Glenmark Pharmaceuticals, USA, has announced the commercial launch of its epinephrine injection USP, 30 mg/30 mL (1 mg/mL) multiple-dose epinephrine vial in the US pharmaceutical market. The product expands Glenmark’s hospital injectables portfol...
A new era is unfolding in India’s pharmaceutical landscape in 2025, where innovation, collaboration, and regulatory rigor are driving transformative growth.
.jpg)
, CDSCO.jpg)